Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Federal Trade Commission
AstraZeneca
Deloitte
US Department of Justice
Medtronic
Chinese Patent Office
Daiichi Sankyo
Merck
Chubb

Generated: February 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022522

« Back to Dashboard

NDA 022522 describes DALIRESP, which is a drug marketed by Astrazeneca Pharms and is included in one NDA. It is available from two suppliers. There are six patents protecting this drug and one Paragraph IV challenge. Additional details are available on the DALIRESP profile page.

The generic ingredient in DALIRESP is roflumilast. There are nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the roflumilast profile page.
Summary for 022522
Tradename:DALIRESP
Applicant:Astrazeneca Pharms
Ingredient:roflumilast
Patents:6
Pharmacology for NDA: 022522
Suppliers and Packaging for NDA: 022522
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DALIRESP roflumilast TABLET;ORAL 022522 NDA AstraZeneca Pharmaceuticals LP 0310-0088 N 0310-0088-28
DALIRESP roflumilast TABLET;ORAL 022522 NDA AstraZeneca Pharmaceuticals LP 0310-0088 N 0310-0088-95

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength500MCG
Approval Date:Feb 28, 2011TE:RLD:Yes
Regulatory Exclusivity Expiration:Aug 31, 2020
Regulatory Exclusivity Use:INFORMATION ADDED TO THE LABELING TO INCLUDE RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS
Regulatory Exclusivity Expiration:Jan 23, 2021
Regulatory Exclusivity Use:NEW STRENGTH
Patent:➤ Try a Free TrialPatent Expiration:Jan 27, 2020Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Deloitte
Fuji
Cerilliant
Colorcon
Cantor Fitzgerald
Express Scripts
Daiichi Sankyo
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot